INTRODUCTION

The most popular route of administration of the drug is oral route because it is simple and convenient way of administering drugs. Most of the newly developed drug shows poor solubility and absorption after oral administration despite their high permeability. During the development of new compounds the problem of great concern to scientists is solubility and dissolution. Recently various solubilization technologies have been developed to solve this challenge such as, solid dispersions, micronization, nanocrystallization, cyclodextrin complexes, micellar solubilization and liquisolid formulations and many more. From these available technologies, solid dispersion (SD) method found promising results which enhances the solubility, dissolution and bioavailability. These can be defined as molecular mixtures of poorly water-soluble drugs in hydrophilic carriers. The dissolution characteristics enhancement of SDs are due to reduction in the drug particle size and the subsequent increase in the surface area, and improved wettability resulting from inmost contact with a hydrophilic carrier. Pharmaceutical dispersion systems such as, suspension system, colloidal system and solution system and amongst these the most popular systems are solid dispersion (SDs), lipid-based dispersion and liquisolid dispersion.

For solid dispersions, polymeric carriers have used since long time, because of their ability to produce amorphous solid dispersions. They are classified as, natural based and synthetic polymers. Natural polymers mostly used are hydroxypropyl methylcellulose, ethylcellulose and propylcellulose. Synthetic polymers include povidone, polyethylene glycols and poly(methacrylates). The present review article deals with all the important strategies of solid dispersion techniques and their applications in pharmaceutical dosage form development.

STRATEGIES IN SOLID DISPERSION MANUFACTURING METHODS

SD can be prepared by several methods such as solvent evaporation, melting, and supercritical fluid (SCF) technology as shown in figure 1.

Keywords: Solid dispersion, Bioavailability, Solubility, Dissolution parameters, Polymeric carrier
Solvent Evaporation:
The solvent evaporation method is one of the most popular method used for improving solubility and dissolution of water insoluble drugs. The basic principle of this method is that drug and carrier are dissolved in a common solvent for homogeneous mixing. The main advantage of the solvent method is thermal decomposition of drugs or carriers can be prevented because of the relatively low temperatures required for the evaporation of organic solvents.14-15

Choi JS, et al develop a dutasteride (DUT) solid dispersion with various co-polymers using a solvent evaporation method to enhance its dissolution and oral bioavailability. Tocopheryl polyethylene glycol-1000-succinate was chosen as the solubilizer and microcrystalline cellulose as a carrier. There was increase in the dissolution rate and bioavailability of the drug due to the hydrogen interaction between drug and the polymer.16 Xiaojing Xia, et al develop anovel formulation of oleanolic acid (OA) solid dispersion (SD), using leucine (Leu) as the carrier to improve OA oral bioavailability by solvent evaporation. OA-Leu SD found to show higher relative oral bioavailability than free OA.17 Xu Cheng, et al develop Efodiripine hydrochloride solid dispersion by solvent evaporation method with HPMCAS as matrix and urea as a pH adjusting agent. Excellent IVIVC for solid dispersions and crude drug was obtained for the dissolution rate.18 Shahram Emami et al develops sirolimus solid dispersions by solvent evaporation technique using Polyvinylpyrrolidone (PVP), Poloxamer 188 and Cremophore RH40. More than 75% of sirolimus was released within 30 minutes from all prepared solid dispersions.19

Jingjing Tang et al developed febuxostat (FB) solid dispersion through solvent evaporation. Solid dispersion composed of FB, polyvinylpyrrolidone (PVP K30) and poloxamer. A remarkable increase was observed in the optimised formulation in saturation solubility, dissolution studies, and bioavailability.20 Sung Jin Kim et al developed tacigrelor solid dispersion prepared via solvent evaporation method using ethanol, TPGS and Neusilin® US2 selected for preparing formulation. The released parameter of the optimized solid dispersion significantly increased in comparison with physical mixture. The solid dispersion formulation improved the peak plasma concentration (Cmax) and relative bioavailability compared to that of pure drug.21

Ahmed M Amer et al formulated candesartan cilexetil (CC) nanocrystals via solid dispersion (SD) technique using tromethamine (Tris) by solvent evaporation at different drug carrier ratios. A burst drug release followed by an improved dissolution was observed indicating instant formation of nanocrystals along with amorphization.22 Xing Chen et al developed solid dispersions of the poorly soluble drug progesterone (PG) using hydroxypropyl methylcellulose (HPMC), hydroxypropyl methylcellulose acetate succinate (HPMCAS), microcrystalline cellulose (MCC), polyvinylpyrrolidone (PVP) and silica (SiO2), by, solvent evaporation (SE) and co-milling method (BM) with the aim to evaluate the impact of processing methods and carriers on the physicochemical properties of solid dispersions of PG. They concluded that, drug solubility improves by SE, but BM provides better results which clearly, indicates that intermolecular forces are more efficient than the solvent mediated.23

Dingkun Zhang et al developed Andrographolide (ADG) solid dispersion using silica (SiO2) as a carrier by solvent evaporation method. SD formed a unique structure to disperse the drug and release drug rapidly to improve the dissolution of ADG.24 Muhammad Tayyab Ansari et al developed solid dispersions (SDs) of artemether by solvent evaporation using artemether and polyethylene glycol 6000; self-emulsified solid dispersions (SESds) containing artemether, polyethylene glycol 6000, cremophor-A-25, olive oil, ethoxypropylmethylcellulose and transculto. The results clearly demonstrated the increase in aqueous solubility of artemether.25

Hot melt extrusion:
Hot-melt extrusion is a method for improving solubility of poorly water-soluble drugs, in which the amorphous SD is formed without solvent. This method is carried out by a combination of the melting method and an extruder, in which drug and carriers are simultaneously mixed, heated, melted, homogenized, and extruded into rods, tablets, milled or pellets.26 The advantages of this technique are that it avoids the degradation of drug during the melting.27

Figure 1: Various manufacturing methods of solid dispersions

Methods to manufacture solid dispersion
- Kneading method
- Melting
- Solvent evaporation
- Melting solvent
- Hot melt extrusion
- Melting method
- Melt agglomeration
- Solvent evaporation
- Spray drying
- Lyophilization
- Supercritical fluid
- Co-precipitation
- Electrospinning

ISSN: 2250-1177CODEN (USA): JDDTAO
Ting Wen et al developed Fenofibrate (FNB) amorphous solid dispersion employing PVP VA64 as the carrier by hot-melt extrusion method. The prepared FNB-SD was found to be an amorphous state after hot-melt extrusion process. They also concluded that, PVP VA64 could be used as a polymer to enhance the bioavailability of poorly water-soluble drugs using hot-melt extrusion. 28Yiyan Zhang et al developed baicalin to prepare solid dispersions using hot melt extrusion (HME). Kollidon VA64 and Eudragit EPO were selected as two carriers. After oral administration, the relative bioavailability of solid dispersions with VA64 and EPO was found to be greater as compared with pure drug, respectively.29 Ashish L Sarode et al developed solid dispersion of poorly water soluble drugs Indomethacin (IND), Itraconazole (ITZ), and Griseofulvin (GSP) and hydrophilic polymers - Eudragit EPO, Eudragit L-100-55, Eudragit L-100, HPMCAS-LF, HPMCAS-MF, Pharmacoint 603, and Kollidon VA-64 by HME. The highest dissolution rate and supersaturation of poorly water-soluble drugs could be attributed to drug-polymer interactions occurred during HME.30Uttam Nandi et al, introduced smectite clay matrices as a drug delivery carrier for the development of Indomethacin (IND) amorphous solid dispersions (ASD). Indomethacin (IND) was processed with two different smectite clays, magnesium aluminium and lithium magnesium sodium silicates, using hot melt extrusion (HME) to prepare solid dispersions. The researcher reported that amorphous solid dispersion prepared using inorganic smectite clay particles can effectively increase the dissolution rate of IND.31 Arun Butreddy et al., reviewed on approaches to overcome the solubility and bioavailability limitations of poorly soluble active pharmaceutical ingredients is the development of amorphous solid dispersions (ASDs) using hot-melt extrusion (HME) technique. It focused on the prediction of drug-polymer miscibility, the elements and sequence of QbD, and various screening and optimization designs, to provide insights into the formulation and process variables that are encountered routinely in the production of HME-based ASDs.12Zilin Feng, et al, developed carbamazepine (CBZ) loaded solid dispersions using Eudragit EPO as carrier by hot-melt extrusion. The results showed that, the CBZ SDs prepared by HME with CBZ and Eudragit EPO could improve the dissolution and dissolution rate.33Fei Yun, et al, developed osthol (OS), a coumarin derivative were prepared with various polymers including Plasdone S-630, HPMC-E5, Eudragit EPO, and Soluplus by hot-melt extrusion method. In comparison to the untreated OS coarse powder and the physical mixture with polymers, the solid dispersions prepared with Plasdone S-630 or HPMC-E5 (drug/polymer: 1:6) showed a significant enhancement of dissolution rate (∼3-fold higher D30).34Long Xi, et al, formulated amorphous solid dispersions (ASDs) of Lacidipine using hot-melt extrusion (HME) with Soluplus and PVP VA64 at a drug/carrier ratio of 1:10 (w/w). In vitro dissolution rates of the optimal formulations were extremely enhanced compared to bulk Lacidipine. The ASD formulated with Soluplus showed better physical stability than that with PVP VA64. Lacidipine ASD formulated with Soluplus showed a significant increase in in vitro dissolution rate and favorable physical stability in the stress test.35 Arias MJ, et al, developed new solid dispersion system of Triamterene, a poorly soluble drug, to increase the dissolution rate and oral bioavailability. They prepared SDs by the melting carrier method using D-mannitol as matrix.36

**Melt agglomeration**

Melt agglomeration technique is a process where the binder acts as a carrier. SD(s) is prepared either by heating the binder, drug and excipient to a temperature above the melting point of the binder or by spraying a dispersion of drug in molten binder on the heated excipient by using a high shear mixer.37-38 Anette Seo, et al, developed solid dispersions of diazepam by melt agglomeration techniques in order to evaluate the possibility of improving the dissolution rate. Lactose monohydrate was melt agglomerated with polyethylene glycol (PEG) 3000 or Gelucire 50/13 (mixture of glycereides and PEG esters of fatty acids) as meltable binders in a high shear mixer. It was found to increase the dissolution rate of diazepam by melt agglomeration. A higher dissolution rate was obtained with a lower drug concentration.39Anna Cecilia Jørgensen, et al, investigated the effect of cooling mode and storage conditions on the dissolution rate of a solid dispersion prepared by melt agglomeration. The cooling mode had an effect on the dissolution rate, probably due to several factors such as the morphology of the agglomerates and crystallinity of the carrier. The dissolution increased with increasing temperature and relative humidity which increased the amount of water sorbed in the carrier.40 Thomas Vilhelmsen et al, developed a solid dispersions of poorly soluble drug Lu-X, by melt agglomeration in rotary processor. They investigated effects of binder type and method of manufacturing on the dissolution profile of Lu-X. Lactose monohydrate and Lu-X was melt agglomerated with Rylo MG12, Gelucire 50/13, PEG 3000, or poloxamer 188. The melt-in procedure gave a higher dissolution rate than the spray-on procedure.41 Sachin Gahoi, et al, prepared agglomerates by Atomized Melt Agglomeration (AMA) containing solid dispersion of lumefantrine. Lumefantrine and lactose were melt agglomerated using atomized molten polyethylene glycol (PEG) 6000 or Poloxamer 188 in a fluidized bed as binder/carrier. A significant enhancement in the in vitro dissolution profiles of the agglomerates was observed compared to the pure drug and drug-excipient physical mixtures.42

**Spray drying method**

Spray-drying commonly used method in the production of solid dispersions. It consists of dissolving or suspending the drug and carrier, and then spraying it into a stream of heated air to flow to remove the solvent. Due to the large specific surface area offered by the droplets, the solvent rapidly evaporates and the solid dispersion is formed within seconds, which may be fast enough to prevent phase separation.43Noriko Ogawa et al., prepared and characterized solid dispersion particles of Indomethacin (IMC) with amphiphilic polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, as a water-soluble carrier and d-mannitol (W/N) was used as an excipient by hot-melt extrusion and spray drying. The results depict that, dissolution behavior of the drug crystal could be improved by solid dispersion with the polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer.44Gabriela Ruphy, et al, developed amorphous solid dispersions of ibuprofen and curcumin based on yeast glucan particles by spray drying. It was possible to produce completely amorphous composites with outstanding wettability and dispersion properties, and with significantly faster dissolution rates when compared to the micronized crude drug.45 Surendra Poudel, et al, developed a Candesartan cilexetil (CC) loaded amorphous solid dispersions with a hydrophilic carrier (PVPK30) and pH modifier using the spray drying technique. They found that, optimized formulation exhibited a 30,000-fold increase in solubility and a more than 9-fold enhancement in dissolution compared to pure drug.46Varsha Pokharkar, et al, prepared pioglitazone
solid dispersion by the spray drying method using hydrophilic polymers such as PVP K17, PVP K30, and HPMC E3. Results showed that there was significant improvement in solubility and dissolution rate in solid dispersion containing PVP K17 than in that of the pure drug.67

Annelles Smeets, et al., prepared amorphous solid dispersions of darunavir and hydroxpropyl methylcellulose (HPMC), hydroxypropyl methylcellulose acetate succinate (HPMC AS) and polyvinylpyrrolidone K-30 (PVP) with electrospaying and spray drying, in order to compare both solvent based manufacturing techniques. The formulations prepared with the two methods were amorphous and had similar characteristics concerning the residual solvent and drug release. Mouhamad, et al., prepared amorphous solid dispersion (ASD) of Tadalafil (TDL) by spray-drying, using glycryrrhiza-a natural drug carrier. The optimized formulation showed marked increase in dissolution rate compared to pure TDL.49Rahul B Chavan et al developed amorphous solid dispersion (ASD) of nisoldipine. ASD preparation from lab scale formulation technique to scalable spray drying technique. Lab scale ASDs of nisoldipine were prepared using rotary evaporation (solvent evaporation) method and the optimized stable ASDs were scaled up by spray drying. The enhanced solubility was translated to improved dissolution of the drug when compared with crystalline and amorphous form complementing the outcome of the solution state study.50

Emer Browne, et al., compared the particle characteristics and dissolution performance of amorphous solid dispersions (ASDs) of ketoprofen and vinyl-pyrrolidone based polymers prepared using electrospaying and spray drying methods. Electrospaying resulted in powders with higher specific surface area, smaller mean particle size, and narrower particle size distribution relative to the spray-dried material.51Zenia Maria Macellavra, et al., Efavirenz solid dispersion in polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (Soluplus®) using spray-drying technique. Solubility and dissolution rate of EFV was enhanced remarkably in the developed spray-dried solid dispersions, as a function of the polymer concentration.52

Lyophilisation

Lyophilisation process involves immersing the drug carrier solution in liquid nitrogen until the solution at frozen state. The best advantage is that it reduces the risk of phase separation and disadvantage is that the most of the organic solvent do not stay frozen due to low freezing temperature.53Muhammad Asad Saeed, et al., developed Artesunate solid dispersions through solvent evaporation and freeze-drying techniques using polyethylene glycol 4000 (PEG4000) as solubility enhancer. Maximum increase in solubility was attained by freeze-dried solid dispersions i.e., 2.99 folds and 2.66 folds by solvent evaporation solid dispersion as compare to pure drug.54Lili Fitriani, et al., prepared and characterized solid dispersion of efavirenz – polyvinylpyrrolidone (PVP) K-30 by freeze drying with the aim to increase its solubility. They developed solid dispersion of Efavirenz - PVP K-30 by solvent evaporation method and dried using a freeze dryer. The researcher concluded that, the solubility of solid dispersion increased significantly than solubility of pure drug.55Mona Basha, et al., developed Famotidine(FM) solid dispersion using the novel copolymer, Soluplus® (SP) by kneading and freeze-drying techniques at various FM:SP ratios. FM solid dispersion prepared at 1:10 ratio using freeze drying manifested the highest saturation solubility, having smooth porous surface with the complete conversion of FM to the amorphous form.56Mohamad Khdser, et al., developed solid dispersions of prednisolone (PRD) and bovine serum albumin (BSA) by spray drying and freeze-drying methods using a PRD:BSA solution. In-vitro dissolution and release studies showed remarkable increase in dissolution profile.57

P Dansprasit, et al., prepared solid dispersions of diclofenac sodium (DS) by freeze-drying technique, using ethylcellulose (EC) and chitosan (CS) as single and combined carriers. The solid-dispersion capsule containing 5% Expolabt was found to provide the most similar dissolution profile to the one obtained with the solid-dispersion powder.58Juan J Garcia-Rodriguez, et al., developedMebendazole (MBZ) solid dispersions containing different proportions of low-substituted hydroxypropylcellulose (L-HPC) by lyophilization process. In dissolution studies there is marked increase in the dissolution rate in comparison with recrystallized drug.59Shamandeep Kaur, et al., developed Exemestane loaded phospholipid/sodium deoxycholate solid dispersions (EXE-PL/SDC-SDs) on the solubility and oral bioavailability of Exemestane by freeze dyeing technique. Lyophilized formulation exhibits a significant increase in solubility and dissolution rate as compared to free drug Exemestane.60Wei-Juan Xu, et al., developed valsartan (VAL) SDs by a freeze-drying technique with polyethylene glycol 6000 (PEG6000) and hydroxypropylmethylcellulose as hydrophilic polymers, sodium hydroxide (NaOH) as an alkalizer, and poloxamer 188 as a surfactant without using any organic solvents. The dissolution rates of the SDs were significantly improved at pH 1.2 and pH 6.8 compared to those of the pure drug.61Khater A. S. Al-japairei, et al., developed solid dispersion (SD) of Telmisartan formulation as a ternary mixture of a drug, a polymeric carrier (poly (vinylpyrrolidone) (PVP) K30), and an alkalizer (Na2CO3) by lyophilization. The developed SD formulations resulted in significant improvement in in vitro dissolution compared to pure drug.62K Wlodarski, developed tadalafil (Td) six different solid dispersions in the following polymers: HPMC, MC, PVP, PVP-VA, Kollicoat IR and Soluplus by freeze-drying. Apparent solubility and intrinsic dissolution rate studies revealed the greatest, a 16-fold, increase in drug solubility and a significant, 20-fold, dissolution rate enhancement for the Td/PVP-VA solid dispersion in comparison with crystalline Td.63

Fusion method

In fusion technique, the molecular dispersion is formed due to the mixing caused by molecular mobility of drug and carrier molecules, which are greatest at the melting point of the two components of the dispersion.Zack Guo, et al., developed acoustic fusion to form amorphous solid dispersions (ASD) of a torcetrapib, itraconazole, and lopinavir, with a variety of polymer systems, including HPMCAS (L, M, and H), copovidone, Soluplus, PEG5150, Vitamin-E TPGS, Kolliphor EL, and Eudragit, etc. Formulations of these ASD drug products demonstrated increase in solubility of the drug substance compared to the solubility of the crystalline form of the drug.64Shamsuddin, et al., developed SD of spironolactone (SPL) using an inert carrier polyethylene glycol 4000 (PEG 4000) by the conventional fusion method. The solubility of SPL SD was found to be significantly increased as compared to SPL active pharmaceutical ingredient (API) and physical mixture of PEG 4000 and SPL.65Guanhao Ye, et al., developed solid dispersions of itraconazole with Eudragit E100, a hydrophilic polymer, by a simple fusion method. Powdered solid dispersion and pellets prepared showed approximately 30- and 70-fold increases in dissolution rate over the pure drug, respectively.66
P T Koh, et al., developed solid dispersion of Efavirenz using polyethylene glycol 8000, polyvinylpyrrolidone K30 alone and combination of both by solvent and fusion method. Dissolution was remarkably improved in both systems compared to pure efavirenz. Binary and ternary solid dispersion systems both have showed a significant improvement in the dissolution rate of efavirenz.78Rammani Prasad, et al., developed solid dispersions of furosemide with Soluplus® by solvent evaporation and fusion methods. Solid dispersions prepared by fusion method exhibited faster drug release compared to those prepared by solvent evaporation.68Hemanth Annepogu, et al., prepared solid dispersion of thiocolchicoside (TCS) using poloxamer carriers. Poloxamer-188 was the best for increasing the solubility and release rate of TCS from the SDs.79Amjad Hussain, et al., prepare solid dispersions (SDs) of Piroxicam Solutol and Gelucire by applying fusion method. Results revealed that the solubility value of drug was increased by 20-25 times (with Solutol) and 6-10 times (with Gelucire).80Mohd Aftab Alam, et al., developed effervescence assisted solid dispersion (EASD) technique by using modified fusion method by adding effervescence couple comprising organic acid (citric acid) and carbonic base (sodium bicarbonate). Solubility of atorvastatin calcium, cetuximab axetil, clotrimazole, ketoconazole (from 16 to 500 μg/ml), and metronidazole benzate (from 112 to 208 μg/ml) in EASDs was enhanced by 3.45, 4.4, 10.7, 31.2, and 1.8-fold, respectively.71

**Supercritical fluid technology**

Supercritical fluid methods are mostly applied with carbon dioxide (CO2), which is used as either a solvent for drug and matrix or as an anti-solvent. This technique consists of dissolving the drug and the carrier in a common solvent that is introduced into a particle formation vessel through a nozzle, simultaneously with CO2. When the solution is sprayed, the solvent is rapidly extracted by the SCF, resulting in the precipitation of solid dispersion particles on the walls and bottom of the vessel. The use of processes using SCF reduces particle size, residual solvent content, without any degradation and often results in high yield.32Fei Han, et al., developed solid dispersions of ibuprofen (IBU) by supercritical fluid (SCF) technology. The dissolution performance of the SCF-prepared IBU dispersions was significantly improved compared to that of the physical mixtures of crystalline IBU and a polymer.78Bashar Altaani, et al., developed solid dispersions atorvastatin by supercritical CO2 technology by using polyvinyl pyrrolidone K30 (PVP), polyethylene glycol 6000 (PEG), Soluplus® and chitosan. Dissolution enhancement of atorvastatin was achieved by preparation of polymeric dispersions of the drug using the supercritical technology without further addition of solvents.77Elena Djuris, et al., developed carvediol (CARV) solid dispersions with the selected (co)polymers (polyvinylpyrrolidone (PVP), hydroxypropyl methylcellulose (HPMC), Soluplus® and Eudragit®) with supercritical CO2 assisted method. Results confirmed with the highest dissolution efficiency of CARV-PVP and CARV-HPMC solid dispersions.82Rana M Obaidat, et al., developed solid dispersions of tacrolimus with soluplus, PVP, HPMC, and porous chitosan with supercritical fluid technology. TPGS was used as a surfactant additive with chitosan, HPMC, and PVP. Significant improvement for the release profile was achieved for the prepared dispersions.75

Rujie Yang, et al., prepared solid dispersion (SD) of a CoQ10 by supercritical fluid technology with fumed silica as a carrier. In vitro drug release, the dissolution of coenzyme Q10 in solid dispersion improved by 78.8% compared with commercial tablets.83SeoungWook Jun, et al., developed Cefuroxime axetil (CA) solid dispersions with HPMC 2910/PVP K-30 using solution enhanced dispersion by supercritical fluid (SCF) technology. Dissolution studies indicated that the dissolution rates were remarkably increased in solid dispersions compared with those in the physical mixture and drug alone.77Jibin Guan, et al., developed solid dispersion of glyburide using supercritical fluid (SCF) technology. The glyburide silica-based dispersion could also be compressed into tablet form. In vitro drug release analysis of the silica solid dispersion tablets demonstrated faster release of glyburide compared with the commercial micronized tablet.78Cuifang Cai, et al., developed solid dispersion (SD) of bifendate by silica as polymer using supercritical carbon dioxide (ScCO2) technology. In vitro dissolution rate was significantly improved with cumulative release of 67% within 20 min relative to 8% for the physical mixture of bifendate and silica.79

Hui Liu, et al., developed solid dispersions of budesonide by supercritical fluid (SCF) technique, using poly (ethylene oxide) (PEO) as a hydrophilic carrier. The enhanced dissolution rates of budesonide were observed from SCF-treated budesonide-PEO mixtures. budesonide-PEO solid dispersions with enhanced dissolution rate can be prepared using organic solvent-free SCF process.80Rana M Obaidat, et al., developed cefixime trihydrate solid dispersions using conventional methods and supercritical fluid technology with different polymers (polyethylene glycol 4000 and 6000 and Soluplus). The solubility of the prepared solid dispersions increased except for those prepared with Soluplus® using supercritical fluid technology without co-solvent. The best enhancement in the release profile was recorded by Soluplus®-based solid dispersions prepared using a conventional method.81Nicola De Zordi, et al., developed Furosemide solid dispersion using the hydrophilic polymer Crospovidone by supercritical anti-solvent techniques (SASs). Best in vitro dissolution performance in the simulated gastric fluid (pH 1.2) was obtained, in comparison with the same SD obtained by traditional method.82

**Co-precipitation**

Co-precipitation is a technique for increasing the dissolution of poorly water-soluble drugs, so as to consequently improve bioavailability.83Praveen Reddy Palani, et al., prepared amorphous solid dispersions (ASDs) of quercetin (Que) using HPMCAS-HF, HPMCAS-MF and HPMCAS-LF as carriers by co-precipitation. The Que ASD based on PVP K30 was prepared by solvent evaporation method. The Que/MF ASD exhibited better dissolution behavior compared to the Que/K30 ASD.84Amanda K.P. Mann, et al., developed amorphous solid dispersions of compound A, and copovidone were made by conventional spray drying and co-precipitation. The amorphous dispersions were then formulated and tableted. The co-precipitation tablets had slightly slower dissolution than the spray-dried dispersion.84

Zedong Dong, et al., developed solid dispersions of Compound A in Hypromellose acetate succinate (HPMC-AS) prepared by hot-melt extrusion (HME) and solvent co-precipitation (CP) processes. Dissolution study showed that the CP product had a faster dissolution profile, but slower intrinsic dissolution rate than the HME product.85Sonal V Bhujbal, et al., developed amorphous solid dispersion (ASD) of lumefantrine with spray anti-solvent precipitation using hydroxypropylmethylcellulose phthalate (HPMCP), hydroxypropylmethylcellulose acetate succinate (HPMCAS), poly(methacrylic acid-ethyl acrylate) (EL100) and cellulose acetate phthalate (CAP) as excipients at various drug-polymer ratios. HPMCP and HPMCAS ASDs also achieved
greater drug release levels in the dissolution study than other polymers.86

DalwadiSonali, et al., developed silymarin solid dispersions using HPMC E 15LV by kneading, spray drying and co-precipitation methods. Increase in dissolution compared to pure drug was found as: co-precipitation > spray drying > kneading methodology. The co-precipitation method proved to be best and provided a stable amorphous solid dispersion with improved dissolution compared to the pure drug.87 Hao HelenHou, et al., developed amorphous solid dispersion of GDC-0810 using spray drying, coprecipitation using overhead mixing and coprecipitation using resonant acoustic mixing to generate amorphous solid dispersions (ASDs) of 50% GDC-0810 with hydroxypropylmethylcellulose acetate succinate. Coprecipitated ASD powders (overhead mixing and resonant acoustic mixing) demonstrated superior tablettability and flow properties when compared to the spray drying powder.88

Electrospinning

Electrospinning is one of the novel and popular method in solid dispersion due to its effectiveness, low cost, and the properties of the electrospun nanoparticles.89

This method uses electrical energy to induce changes from liquid to solid where, the drug - polymer solution is subjected to potential between 5 and 30 kV and when electric field removes the surfac
ing to solid where, the drug - polymer solution is subjected to potential between 5 and 30 kV and when electric field removes the surfac
ing to solid where, the drug - polymer solution is subjected to potential between 5 and 30 kV and when electric field removes the surfac
ing to solid where, the drug - polymer solution is subjected to potential between 5 and 30 kV and when electric field removes the surfac
ing to solid where, the drug - polymer solution is subjected to potential between 5 and 30 kV and when electric field removes the surfac
ing to solid where, the drug - polymer solution is subjected to potential between 5 and 30 kV and when electric field removes the surfac
ing to solid where, the drug - polymer solution is subjected to potential between 5 and 30 kV and when electric field removes the surfac
ing to solid where, the drug - polymer solution is subjected to potential between 5 and 30 kV and when electric field removes the surfac

Ahmad Ziaee, et al., developed amorphous solid dispersion (ASD) of ibuprofen (IBU) with two cellulosic excipients, HPMCAS and HPMCP-HP55 employing electrospinning (ES), spray-drying (SD) and rotary evaporation (RE) solvent-based techniques. Dissolution studies showed that electrospun samples had the highest API release rate due to

Table 1* Summary related to overall techniques used recently with continually used polymer

<table>
<thead>
<tr>
<th>SD Techniques</th>
<th>Drugs</th>
<th>Polymers</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Solvent evaporation</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dutasteride (DUT)</td>
<td>Microcrystalline cellulose</td>
<td>[16]</td>
<td></td>
</tr>
<tr>
<td>Oleanolic acid (OA)</td>
<td>Leucine</td>
<td>[17]</td>
<td></td>
</tr>
<tr>
<td>Efonidipine hydrochloride</td>
<td>HPMC-AS</td>
<td>[18]</td>
<td></td>
</tr>
<tr>
<td>Sirolimus</td>
<td>Polylvinlypyrrolidone (PVP), Poloxamer 188 and Cremophore RH40</td>
<td>[19]</td>
<td></td>
</tr>
<tr>
<td>Febuxostat (FB)</td>
<td>Polylvinlypyrrolidone (PVP K30) and poloxamer</td>
<td>[20]</td>
<td></td>
</tr>
<tr>
<td>Ticagrelor</td>
<td>TPGS and Neusilin® US2</td>
<td>[21]</td>
<td></td>
</tr>
<tr>
<td>Candesartan cilexetil (CC)</td>
<td>Tromethamine (Tris)</td>
<td>[22]</td>
<td></td>
</tr>
<tr>
<td>Progesterone (PG)</td>
<td>Hydroxypropyl methylcellulose (HPMC), Hydroxypropyl methylcellulose acetate succinate (HPMCAS), Microcrystalline cellulose (MCC), Polyvinylpyrrolidone (PVP) and silica (SiO2)</td>
<td>[23]</td>
<td></td>
</tr>
<tr>
<td>Andrographolide (ADG)</td>
<td>Silica (SiO2)</td>
<td>[24]</td>
<td></td>
</tr>
<tr>
<td><strong>Hot melt extrusion</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fenofibrate (PBN)</td>
<td>PVP VA64</td>
<td>[28]</td>
<td></td>
</tr>
<tr>
<td>Baicalein</td>
<td>Kollidon VA64 and Eudragit EPO</td>
<td>[29]</td>
<td></td>
</tr>
<tr>
<td>Indomethacin (IND), Itraconazole (ITZ), and Griseofulvin (GSP)</td>
<td>Eudragit EPO, Eudragit L-100-55, Eudragit L-100, HPMCAS-LF, HPMCAS-MF, Pharmacoat 603, and Kollidon VA-64</td>
<td>[30]</td>
<td></td>
</tr>
<tr>
<td>Indomethacin (IND)</td>
<td>Magnesium aluminium and lithium magnesium sodium silicates</td>
<td>[31]</td>
<td></td>
</tr>
<tr>
<td>Carbamazepine (CBZ)</td>
<td>Eudragit EPO</td>
<td>[33]</td>
<td></td>
</tr>
<tr>
<td>Osthole (OS)</td>
<td>Plasdone S-630, HPMC-E5, Eudragit EPO, and Soluplus</td>
<td>[34]</td>
<td></td>
</tr>
<tr>
<td>Melt agglomeration</td>
<td>Lidocaine</td>
<td>Soluplus and PVP VA64</td>
<td>[35]</td>
</tr>
<tr>
<td>--------------------</td>
<td>-----------</td>
<td>-----------------------</td>
<td>-----</td>
</tr>
<tr>
<td>Triamterene</td>
<td>D-mannitol</td>
<td></td>
<td>[36]</td>
</tr>
<tr>
<td>Diazepam</td>
<td>Poloxyl 3000 or Gelucire 50/13</td>
<td>[39]</td>
<td></td>
</tr>
<tr>
<td>Lu-X</td>
<td>Rylo MG12, Gelucire 50/13, PEG 3000, or poloxamer 188</td>
<td>[41]</td>
<td></td>
</tr>
<tr>
<td>Lumeofantrine</td>
<td>Poloxyl 6000 or Poloxamer 188</td>
<td>[42]</td>
<td></td>
</tr>
<tr>
<td>Spray drying method</td>
<td>Indomethacin (IMC)</td>
<td>Polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol</td>
<td>[44]</td>
</tr>
<tr>
<td>Ibuprofen</td>
<td>Curcumin</td>
<td></td>
<td>[45]</td>
</tr>
<tr>
<td>Candesartan cilexil (CC)</td>
<td>PVPK30</td>
<td>[46]</td>
<td></td>
</tr>
<tr>
<td>Pioglitazone</td>
<td>PVP K17, PVP K30, and HPMC E3</td>
<td>[47]</td>
<td></td>
</tr>
<tr>
<td>Darunavir</td>
<td>Hydroxypropyl methylcellulose (HPMC), hydroxypropyl methylcellulose acetate succinate (HPMC AS) and polyvinylpyrrolidone K-30 (PVP)</td>
<td>[48]</td>
<td></td>
</tr>
<tr>
<td>Tadalafil (TDL)</td>
<td>Glycyrrhizin</td>
<td></td>
<td>[49]</td>
</tr>
<tr>
<td>Nisoldipine</td>
<td>Poloxyl 4000 (PEG4000)</td>
<td>[50]</td>
<td></td>
</tr>
<tr>
<td>Ketoprofen</td>
<td>vinyl-pyrrolidone based polymers</td>
<td>[51]</td>
<td></td>
</tr>
<tr>
<td>Efavirenz</td>
<td>Polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (Soluplus®)</td>
<td>[52]</td>
<td></td>
</tr>
<tr>
<td>Lyophilization</td>
<td>Efavirenz</td>
<td>Polyvinylpyrrolidone (PVP) K-30</td>
<td>[55]</td>
</tr>
<tr>
<td>Famotidine</td>
<td>Soluplus® (SP)</td>
<td></td>
<td>[56]</td>
</tr>
<tr>
<td>Prednisolone</td>
<td>Bovine serum albumin (BSA)</td>
<td>[57]</td>
<td></td>
</tr>
<tr>
<td>Diclofenac sodium (DS)</td>
<td>Eudrificell E (EChitosan (CS))</td>
<td>[58]</td>
<td></td>
</tr>
<tr>
<td>Mebendazole (MBZ)</td>
<td>low-substituted hydroxypropylcellulose (L-HPC)</td>
<td>[59]</td>
<td></td>
</tr>
<tr>
<td>Exemestane</td>
<td>Phospholipid/sodium deoxycholate</td>
<td>[60]</td>
<td></td>
</tr>
<tr>
<td>Valsartan (VAL)</td>
<td>Poloxyl 6000 (PEG6000) and hydroxypropylmethylcellulose</td>
<td>[61]</td>
<td></td>
</tr>
<tr>
<td>Telmisartan</td>
<td>Poloxylpyrrolidone (PVP) K30</td>
<td>[62]</td>
<td></td>
</tr>
<tr>
<td>Tadalafil (Td)</td>
<td>HPMC, MC, PVP, PVP-VA, Kollicoat IR and Soluplus</td>
<td>[63]</td>
<td></td>
</tr>
<tr>
<td>Fusion method</td>
<td>Torcetrapib, itraconazole, and lopinavir</td>
<td>HPMCAS (L, M, and H), copovidone, Soluplus, PEG1500, Vitamin-ETPGS, Kolliphor EL, and Eudragit</td>
<td>[64]</td>
</tr>
<tr>
<td>Spironolactone (SPL)</td>
<td>Polyoxylon glycol 4000 (PEG 4000)</td>
<td>[65]</td>
<td></td>
</tr>
<tr>
<td>Itraconazole</td>
<td>Eudragit E100</td>
<td>[66]</td>
<td></td>
</tr>
<tr>
<td>Efavirenz</td>
<td>Polyoxylon glycol8000, polyoxylpyrrolidone K30</td>
<td>[67]</td>
<td></td>
</tr>
<tr>
<td>Thiocolchicoside (TCS)</td>
<td>Poloxamer-188</td>
<td>[69]</td>
<td></td>
</tr>
<tr>
<td>Piroxicam</td>
<td>Solutol and Gelucire</td>
<td>[70]</td>
<td></td>
</tr>
<tr>
<td>Atorvastatin calcium, cefuroxime axetil, clotrimazole, letoconazol and metronidazole benzoate</td>
<td>Citric acid and sodium bicarbonate</td>
<td>[71]</td>
<td></td>
</tr>
<tr>
<td>Atorvastatin</td>
<td>Polyoxyl pyrrolidone K30 (PVP), polyoxylon glycol 6000 (PEG), Soluplus®, and chitosan</td>
<td>[73]</td>
<td></td>
</tr>
<tr>
<td>Carvedilol (CARV)</td>
<td>Polyoxylpyrrolidone (PVP), hydroxypropyl methylcellulose (HPMC), Soluplus® and Eudragit®</td>
<td>[74]</td>
<td></td>
</tr>
<tr>
<td>Cefuroxime axetil (CA)</td>
<td>Silica</td>
<td>[77]</td>
<td></td>
</tr>
<tr>
<td>Glyburide</td>
<td>Silica</td>
<td>[78]</td>
<td></td>
</tr>
<tr>
<td>Bifendate</td>
<td>Poly (ethylene oxide) (PEO)</td>
<td>[79]</td>
<td></td>
</tr>
<tr>
<td>Budesonide</td>
<td>Polyoxylon glycol 4000 and 6000 and</td>
<td>[80]</td>
<td></td>
</tr>
</tbody>
</table>

**ISSN: 2250-1177**

**CODEN (USA): JDDTAO**
CONCLUSION

Solid dispersions are one of the systematic technologies for controlling many problems relating to bioavailability of poorly soluble drugs. Still, there has some problem which will be short out by applying novel and present approach. This review focuses on current attempt to short out bioavailability issue and explains various new technologies involved for development of SD. With each continuing approach, we believe that the SD systems will continue to be utilized for formulating poorly soluble drugs.

REFERENCES


70. Hussain A, Farrukh M, Abbas N, Irfan M, Arshad MS, Bukhari NL. Effect of low melting hydrophilic carriers on the solubility and dissolution rate of Piroxicam using solid dispersion technique. Pakistan journal of pharmaceutical sciences. 2019 Sep 1; 32(3 (Supplementary)):2257-60.


